Plavix Tablet, Film Coated
Product Images NDC 0024-1332

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Plavix (NDC 0024-1332). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (De8b0b67 Eb25 4684 83b5 7ad785314227 01)

Chemical structure of clopidogrel, the active ingredient in Plavix, including its molecular components and bonds, depicted with an attached sulfuric acid molecule (H2SO4).*

FDA Label Image

Figure (De8b0b67 Eb25 4684 83b5 7ad785314227 02)

A horizontal bar chart showing the effect of co-administered proton pump inhibitors (PPIs) Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg on active metabolite AUC of Plavix (clopidogrel) compared to Plavix administered alone. The chart includes mean values and 90% confidence intervals, with a change relative to Plavix alone on the x-axis ranging from 0.4 to 1.4.*

FDA Label Image

Figure (De8b0b67 Eb25 4684 83b5 7ad785314227 03)

A line graph presenting cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It compares two groups: Placebo (+ aspirin) and Plavix (+ aspirin), with Plavix showing a lower cumulative event rate throughout the period. The graph includes a statistical significance value (P=0.00009) and notes that other standard therapies were used as appropriate.*

FDA Label Image

Figure (De8b0b67 Eb25 4684 83b5 7ad785314227 04)

Two forest plots presenting hazard ratios with 95% confidence intervals for different subgroups comparing Plavix (clopidogrel) versus placebo. The subgroups include age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, use of Heparin/LMWH, Aspirin dosage, GP IIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use. The plots visualize comparative outcomes favoring either Plavix or placebo across these categories.*

FDA Label Image

Figure (De8b0b67 Eb25 4684 83b5 7ad785314227 05)

A line graph showing percentage of deaths before first discharge over 28 days since randomization, comparing placebo and clopidogrel groups. The placebo group shows 8.1% deaths and the clopidogrel group shows 7.5% deaths, indicating a 7% proportional risk reduction with clopidogrel (p=0.03).*

FDA Label Image

Figure (De8b0b67 Eb25 4684 83b5 7ad785314227 06)

A Kaplan-Meier curve chart showing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. Two curves are shown: one for placebo with a 10.1% event rate, and one for clopidogrel with a 9.2% event rate, indicating a 9% proportional risk reduction for clopidogrel.*

FDA Label Image

Figure (De8b0b67 Eb25 4684 83b5 7ad785314227 07)

A forest plot chart showing odds ratios with 99% confidence intervals comparing Plavix to placebo across various subgroups including gender, age, hours since onset, systolic blood pressure (SBP), heart rate, and fibrinolytic agent use. The plot indicates whether outcomes favor Plavix or placebo, with subgroup counts and percentages for each treatment group included in a table on the left side.*

FDA Label Image

Figure (De8b0b67 Eb25 4684 83b5 7ad785314227 08)

A forest plot chart comparing the hazard ratios with 95% confidence intervals for Plavix (clopidogrel) versus aspirin across qualifying conditions including stroke, myocardial infarction (MI), and peripheral artery disease (PAD). The chart shows patient counts and event percentages for each treatment group, with markers indicating favor towards Plavix or aspirin along a horizontal axis ranging roughly from 0.6 to 1.3 hazard ratio values.*

FDA Label Image

Figure (De8b0b67 Eb25 4684 83b5 7ad785314227 09)

A line graph comparing cumulative event rates (%) of fatal or non-fatal vascular events over months of follow-up (0 to 36 months) for Aspirin and Plavix. The graph plots time on the X-axis and cumulative event rate on the Y-axis, showing two lines labeled 'ASPIRIN' and 'PLAVIX' with a P-value of 0.045 indicated on the chart.*

FDA Label Image

Principal Display Panel (75 mg Tablet Bottle Label)

Label for Plavix (clopidogrel tablets) 75 mg film-coated tablets. The label indicates a package size of 90 tablets. It includes the instruction to dispense with a medication guide. The labeler is Sanofi-Aventis U.S. LLC. The label also shows the National Drug Code (NDC 0024-1171-90) and contains storage instructions and manufacturer information.*

FDA Label Image

Principal Display Panel (300 mg Tablet Blister Pack Carton)

Label for Plavix 300 mg film-coated tablets. The box is blue with white and red text, showing the brand name Plavix and the generic name clopidogrel tablets. It includes details such as quantity (30 tablets), manufacturer Sanofi-Aventis U.S. LLC, storage information, and a medication guide notice. The label also displays contact numbers and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.